Want to see TSE:DOSE full AI Analyst Report?
DOSE Stock Chart & Stats
C$0.14
C$0.02(6.67%)
At close: 4:00 PM EST
C$0.14
C$0.02(6.67%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.24
Previous CloseN/A
Volume31.00K
Average Volume (3M)36.09K
Market Cap
C$13.85M
Enterprise ValueC$18.72M
Total Cash (Recent Filing)C$11.55K
Total Debt (Recent Filing)C$5.32M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding131,886,760
10 Day Avg. Volume35,351
30 Day Avg. Volume36,089
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-2.78
Price to Sales (P/S)7.19
P/FCF Ratio-73.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Patented Delivery PlatformOwning a patented, fast-dissolving oral delivery platform is a durable competitive asset. It supports differentiation versus standard oral formulations, enables licensing or partnership opportunities with drug developers, and creates structural barriers to entry that persist beyond short-term market cycles.
Reduced Cash Burn In Latest YearA visible reduction in cash burn indicates management has improved cost discipline and extended runway. That structural improvement lowers near-term refinancing urgency, increases optionality for executing commercialization or partnerships, and materially affects sustainability over the next several quarters.
Lean Operating StructureA very small headcount signals a lean cost structure and low fixed overhead, which helps conserve cash and enables nimble execution. For a development-stage biopharma firm, lean operations can stretch resources while pursuing partnerships or licensing to scale externally.
Bears Say
Stressed Balance SheetNegative equity combined with higher debt materially reduces financial flexibility. This structural weakness raises refinancing and dilution risk, constrains the ability to fund commercialization, and weakens bargaining power in partner or lender negotiations over the coming quarters.
Volatile And Declining RevenueRevenue volatility and a recent ~29% decline undermine predictable cash generation and signal limited scale or inconsistent product adoption. Over a multi-quarter horizon this reduces the company's ability to demonstrate durable demand to partners or investors and complicates longer-term planning.
Persistent Negative Cash FlowSustained negative operating and free cash flow means the business remains reliant on external capital. Even with reduced burn, ongoing negative cash generation increases the probability of future dilution or onerous financing terms, limiting strategic options and long-term independence.
Rapid Dose Therapeutics Corp News
DOSE FAQ
What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?
Rapid Dose Therapeutics Corp lowest stock price was C$0.08 and its highest was C$0.24 in the past 12 months.
What is Rapid Dose Therapeutics Corp’s market cap?
Rapid Dose Therapeutics Corp’s market cap is C$13.85M.
When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?
Rapid Dose Therapeutics Corp’s upcoming earnings report date is Jul 24, 2026 which is in 22 days.
How were Rapid Dose Therapeutics Corp’s earnings last quarter?
Currently, no data Available
Is Rapid Dose Therapeutics Corp overvalued?
According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued.
Does Rapid Dose Therapeutics Corp pay dividends?
Rapid Dose Therapeutics Corp does not currently pay dividends.
What is Rapid Dose Therapeutics Corp’s EPS estimate?
Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapid Dose Therapeutics Corp have?
Rapid Dose Therapeutics Corp has 131,886,760 shares outstanding.
What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:DOSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.
Technical Analysis
BriaCell Therapeutics
―
Hemostemix
―
Britannia Life Sciences Inc
―
―
Telescope Innovations Corp
―
Options Prices
Currently, No data available
---